Skip to main content
. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498

Figure 4.

Figure 4

Relationship between mutational load and response to immunotherapies targeting PD-1/PD-L1.56 Reprinted by permission from Springer Nature. Yarchoan M, Johnson III BA, Lutz ER et al. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017. NSCLC, non-small cell lung carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; RCC, renal cell carcinoma; SCLC, small cell lung carcinoma.